Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression of vascular endothelial growth factor (VEGF), an endothelial cell-speci®c mitogen and a key mediator of tumor angiogenesis. Here, we identi®ed cis-acting VEGF promoter elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a G+C-rich region at 785 to 750 of the human VEGF promoter was shown to be necessary and sucient for both PDGF inducible and basal expression. The region contains three potential recognition sites for Sp1 transcription factors, which overlap with two Egr-1 sites. Mutations that abolish the ability of Sp1 to interact with the VEGF promoter element also abrogate expression induced by PDGF. Mutations of the potential Egr-1 binding sites did not aect PDGF responsiveness. Gel shift and antibody supershift analyses showed that Sp1 and Sp3 interact constitutively with the VEGF promoter element. Our data strongly suggest that enhanced VEGF gene expression in PDGF-induced NIH3T3 cells is mediated by Sp1 and/or Sp3 transcription factors bound to the 785 to 750 promoter region of the VEGF gene.
Introduction
The growth of solid tumors and the formation of metastases are dependent on the formation of new blood vessels (Folkman and Klagsbrun, 1987) . Vascular endothelial growth factor (VEGF) has been identi®ed as a key mediator of tumor angiogenesis (recently review in Martiny- Baron and MarmeÂ , 1995; Thomas, 1996) . Human tumor biopsies exhibit enhanced expression of VEGF mRNAs by malignant cells and VEGF receptor mRNAs in adjacent endothelial cells (Plate et al., 1992; Weindel et al., 1994) . Interference with the VEGF/VEGF receptor system either by application of anti-VEGF monoclonal antibodies to nude mice which carry VEGF-producing tumor cells, or by retrovirus-driven expression of a dominant-negative mutant of the VEGF receptor¯k-1 in tumor endothelia of such animals resulted in an almost complete inhibition of vascularization and tumor growth (Kim et al., 1993; Millauer et al., 1994) .
Transcription of VEGF mRNA is enhanced by a variety of factors, including platelet-derived growth factor (PDGF)-BB, basic ®broblast growth factor, keratinocyte growth factor, epidermal growth factor, tumor necrosis factor a, transforming growth factor (TGF) a, TGFb1, interleukin-1b, and interleukin 6, in a variety of cultured cells (Finkenzeller et al., 1992; Brogi et al., 1994; Frank et al., 1995; Detmar et al., 1994; Pertovaara et al., 1994; Li et al., 1995; Cohen et al., 1996) . Enhanced VEGF expression has been reported upon activation of protein kinase C by tumor promoters, and in cells harbouring activated oncogenes, such as ras, raf, and src (Grugel et al., 1995; Rak et al., 1995; Mukhopadhyay et al., 1995) . In addition, hypoxia, as well as inactivation of p53 and of von Hippel-Lindau tumor suppressor genes, respectively, result in elevated VEGF mRNA levels (Schweiki et al., 1992; Finkenzeller et al., 1995; Kieser et al., 1994; Siemeister et al., 1996) . Diverse mechanisms acting at the level of promoter activation, mRNA stabilization (Ikeda et al., 1995; Levy et al., 1996) , and translational regulation (Kevil et al., 1996) have been shown to be involved in upregulation of VEGF expression.
In several human pathological settings, including atherosclerosis (Ross, 1993) and various forms of carcinomas, such as osteosarcomas (Betsholtz et al., 1984) , breast carcinomas (Bronzert et al., 1987) , melanomas (Harsh et al., 1990) , and gliomas (Hermanson et al., 1992) , constitutive expression of the c-sis/PDGF-B gene has been observed, whereas its expression is restricted to a small set of cell types in the normal physiological situation. Because the PDGF expressing cells themselves and/or their adjacent cells express PDGF receptors, autocrine and/or paracrine growth promoting circuits were created which induce or support the pathophysiological state.
PDGF stimulates its biological responses by binding to the a and b PDGF receptor tyrosine kinases leading to receptor autophosphorylation. Interaction of a number of intracellular signaling molecules with phosphotyrosine residues on the cytoplasmatic domain of the receptor mediate multiple cellular responses via activation of intracellular signaling pathways (e.g. the Ras/MAP-kinase pathway, for review see: ClaessonWelsh, 1994) . One or several of these signaling pathways may lead to induction of VEGF gene expression upon autocrine and/or paracrine PDGFstimulation of cells. Sequence analysis of the VEGF gene promoter revealed several potential binding sites for the transcription factors AP-1, AP-2, and Sp1 (Tischer et al., 1991) which are candidate mediators of the PDGF signal.
In this report, speci®c nuclear transcription factors were identi®ed that mediate PDGF signal and interact with functional nucleotide elements in the human VEGF gene promoter. Using 5'-deletion and transient transfection analysis, we demonstrated the requirement for the region bp 785 to 750 for PDGF inducible expression. This region contains overlapping potential binding sites for Egr-1 and Sp1/Sp3 transcription factors. Mutations that abolish the ability of Sp1 and/or Sp3 to interact with the VEGF promoter element also abrogate expression induced by PDGF, whereas mutations of the potential Egr-1 binding sites were without eect. Gel shift and supershift studies demonstrated that Sp1 and Sp3, or immunological related factors, bind to the VEGF promoter element in quiescent and in PDGF induced cells. No interaction of a member of the Egr transcription factor family with this element was observed. Thus our data strongly suggest Sp1 and/or Sp3 transcription factors as downstream mediators leading to upregulation of VEGF expression in PDGF-induced cells.
Results

Identi®cation of sequences from the 5'-¯anking region of the VEGF gene required for PDGF inducibility
The promoter region of the human VEGF gene contains several potential consensus binding sites for AP-1, AP-2, Egr-1, and Sp1 transcription factors. To de®ne the regions that confer PDGF-induced promoter activity, a series of 5'-deletion mutants was constructed (Figure 1 ). The various constructs having 5'-ends between 72018 and 752, and a common 3'-end at +50 (relative to the transcriptional start site) were inserted into the luciferase reporter plasmid pAH 1409 and transfected into NIH3T3 cells, which respond with elevated VEGF mRNA levels upon PDGF-BB stimulation (Finkenzeller et al., 1992) . pLuc 2068, which covers the promoter region 72018 to +50, showed a sixfold induction of luciferase activity upon PDGF-BB stimulation as compared to untreated cells. Constructs with various 5'-deletions within the region 72018 to 785 (pLuc 1340, pLuc 840, pLuc 465, pLuc 318, pLuc 135) retained PDGF responsiveness, and the level of induction varied between four-and sixfold (Figure 1 ). In addition, these deletions had no eect on basal promoter activity, which was de®ned as the promoter activity of the constructs in non-treated cells. In contrast, removal of VEGF promoter region 785 to 752 abolished PDGF responsiveness of the construct (pLuc 102) and decreased basal promoter activity by about 90%, indicating that promoter sequences between 785 to 752 confer PDGF activation of the VEGF gene promoter and are essential for basal transcription of the VEGF gene.
VEGF promoter region 785 bp to 750 bp confers PDGF responsiveness to a heterologous thymidine kinase promoter Based on the results of 5'-deletion analysis of VEGF promoter/luciferase constructs, we expected cis-acting elements within the promoter region 785 to 750 to control transcriptional activation of the VEGF gene in response to PDGF. To con®rm whether this promoter region contains enhancer-like elements which confer PDGF responsiveness, plasmid pTATA(785/750) was generated by cloning the 785 to 750 VEGF promoter region in sense orientation in front of a heterologous thymidine kinase promoter/luciferase construct (pTATA; Hecht, 1990) . Transfection of cells with pTATA(785/750) resulted in a tenfold increase in luciferase activity under serum-starved growth conditions as compared to cells transfected with the parental pTATA plasmid. PDGF-BB treatment increased luciferase activity of pTATA(785/750) transfected cells by a factor of 3, whereas pTATA transfected cells did not respond to PDGF-BB ( Figure  2 ). These data indicate that the 785 to 750 region of the human VEGF gene promoter is responsible for basal transcriptional activity and, in addition, confers PDGF responsiveness.
Sp1 consensus recognition sites within the 785 to 750 region are essential for PDGF responsiveness Inspection of the nucleotide sequence of the 785 to 750 region of the human VEGF gene promoter revealed three potential consensus binding sites for transcription factor Sp1, which are overlapping with two potential consensus binding sites for transcription factor Egr-1 (Figure 4a ). To address which of these transcription factors could be a candidate downstream mediator of the PDGF signal, Sp1 and Egr-1 expression in NIH3T3 cells was analysed by Western blot technique, and a mutational analysis of the potential binding sites was performed.
Serum-starved NIH3T3 cells were stimulated with PDGF-BB for various periods of time and protein extracts were subjected to Western blot analysis using Sp1 and Egr-1 antibodies. The Sp1 antibody detected two polypeptide species with apparent molecular masses of 95 kD and 105 kD, which is most probably due to dierential phosphorylation (Jackson et al., 1990) . During the time course of PDGF-BB treatment of the cells, we observed no signi®cant change in Sp1 expression level suggesting that Sp1 is constitutively expressed in NIH3T3 cells (Figure 3a) . In contrast, PDGF-BB treatment of the cells resulted in an transient induction of Egr-1 expression, which became detectable after 30 min, peaked at 60 min, and decreased after 120 min ( Figure 3b ). The Egr-1 antibody detected two protein species of about 85 kD and 90 kD. The slower migrating form, which was most prominent at the peak of Egr-1 expression, most probably represents a hyperphosphorylated form of the protein. These results suggested Egr-1 and not Sp1 transcription factor as a putative downstream element of the PDGF signal pathway leading to stimulation of transcription of the VEGF gene.
To test this hypothesis, a mutational analysis of the consensus Egr-1 and Sp1 binding sites within the 785 to 750 promoter region was performed. pLuc 135/ Egr-1 mut reporter plasmid was constructed by introducing point mutations known to abolish Egr-1 binding (Crosby et al., 1991) into the core sequence (CGGGG to CTAGG) of each of the two potential Egr-1 binding sites within the 785 to 750 region. In reporter plasmid pLuc 135/Sp1 mut mutations known to abolish Sp1 binding (GGGCGG to GTTCGG; Anderson and Freytag, 1991) were introduced into each of the three potential Sp1 binding sites ( Figure  4a ). Transfection assays in NIH3T3 cells revealed that mutation of the potential Egr-1 binding sites did not abolish PDGF responsiveness. An about sevenfold induction of luciferase activity was observed upon transfection of pLuc 135/Egr-1 mut and PDGF-BB stimulation, a value that is in the range of PDGF induction upon transfection of the wild-type VEGF promoter/reporter construct pLuc 135 ( Figure 4b ). In contrast, mutation of the potential Sp1 consensus binding sites abolished PDGF responsiveness of the reporter plasmid and, in addition, decreased basal transcription level of the construct. Thus mutation of the three potential Sp1 binding sites resulted in loss of PDGF responsiveness as it was also observed upon truncation of the 785 to 750 promoter region (pLuc 102). Furthermore, overexpression of Egr-1 in NIH3T3 cells using an Egr-1 expression plasmid (pCMV-Egr-1) did not activate the VEGF promoter constructs (data not shown). These results suggested the consensus Sp1 transcription factor binding sites and not the putative Egr-1 binding sites within the 785 to 750 VEGF gene promoter region to mediate PDGF induced VEGF promoter activity, although Sp1 expression was constitutive whereas Egr-1 expression was induced upon PDGF treatment.
Sp1 and Sp3 transcription factors bind to the 785 to 750 region of the VEGF gene promoter
Next we asked whether members of the Sp1 and/or Egr transcription factor families are able to bind to the potential consensus binding sites within the 785 to 750 promoter region. In addition, we analysed binding of these transcription factors to 785 to 750 promoter fragments which contained the mutations used in transfection assays. Electrophoretic mobility shift assays using a 32 P-labeled double-stranded oligonucleotide which covers the 785 to 750 region of the human VEGF gene promoter, and nuclear extracts from PDGF-stimulated NIH3T3 cells, showed the formation of two prominent nucleo-protein complexes (I and II, Figure 5 are indicated. NIH3T3 cells were transiently transfected with 2 mg of each construct and 1 mg of the b-galactosidase expression plasmid pCMV b-gal, using calcium phosphate precipitation technique. After transfection, cells were serum-starved for 24 h and then stimulated with PDGF-BB (50 ng/ml) for 3 h (+), or left untreated (7). Luciferase activity was normalized for transfection eciency. The experiments were performed in triplicate transcription factors Sp1 and Sp3, or immunological related proteins, are involved in formation of complex II. This result was further con®rmed in competition binding assays using an excess of doubled-stranded oligonucleotides containing the Sp1 consensus sequence which completely suppressed formation of complex II (data not shown). Neither an antibody directed against Egr-1 ( Figure 5 , lane 3), nor antibodies which are directed against other members of the Egr transcription factor family (Egr-2, Egr-3, WT-1), were able to supershift a nucleo-protein complex formed on the VEGF gene promoter fragment (data not shown). Furthermore, mutations of the Sp1 binding sites, which abolished PDGF responsiveness of a reporter gene construct, resulted in loss of complex II formation ( Figure 5 , lanes 6 ± 8). In contrast, complex II formation was still observed using an oligonucleotide probe containing mutations within the putative Egr-1 binding sites ( Figure 5 , lanes 9 ± 11). A major component of complex II, which was formed using this probe, was supershifted by the Sp1 antibody con®rming binding of transcription factor Sp1, or an immunological related protein, to the Egr-1 mutated promoter fragment. In summary, mutations that functionally impaired transcription from the VEGF promoter also eliminated binding of Sp1 and Sp3. The identity of complex I, which was formed with all oligonucleotide probes used in this study, remains unclear so far. In PDGF-BB time course experiments no signi®cant changes in the formation of nucleoprotein complexes on the 785 to 750 region of the human VEGF gene promoter were observed, and in supershift experiments using either Sp1 or Sp3 antibodies we did not detect any variation in the ratio of Sp1 to Sp3 bound to the promoter element (data not shown).
Our results demonstrated that the 785 to 750 region of the human VEGF gene promoter is necessary and sucient to confer PDGF induction of VEGF gene expression. Mutational analysis using reporter gene assays and electrophoretic mobility shift assays identi®ed binding sites for transcription factors Sp1 and Sp3 which mediate PDGF response.
Discussion
VEGF has been identi®ed as a key mediator of tumor angiogenesis. Its expression is induced by a variety of factors including hypoxic growth conditions, activated oncogenes, inactivated tumor suppressor genes, and growth factors (e.g. PDGF-BB). Constitutive expression of the c-sis/PDGF-B gene has been observed in various forms of carcinomas. Binding of PDGF to its receptors results in activation of several intracellular signaling pathways, including the Ras/MAP-kinase pathway, which eventually lead to activation of Here, we used PDGF-BB to identify the cis-acting elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a 36 bp fragment at 785 to 750 of the human VEGF promoter was shown to be necessary and sucient for PDGF inducible and for basal expression. In addition, this fragment is able to confer PDGF responsiveness to a heterologous thymidine kinase promoter. This fragment contains no recognition site for AP-1 transcription factors. In addition, the elimination of AP-1 sites by 5'-deletion analysis of the total VEGF promoter had no signi®cant eect on PDGF-responsiveness. Thus it is unlikely that AP-1 functions as a mediator of the PDGF signal in PDGFinduced VEGF expression. The 785 to 750 VEGF promoter fragment contains three consensus binding sites for transcription factor Sp1/Sp3 which overlap with two consensus Egr-1 sites.
Overlapping Sp1 and Egr-1 transcription factor binding sites were reported to occur in the promoter region of a number of pathophysiologically important genes including PDGF-A, PDGF-B, TGFb1, tissue factor, and urokinase-type plasminogen activator (Khachigian et al., 1996) . A G+C-rich 18 bp element at 770 to 753 of the human PDGF-A gene promoter containing three Sp1 consensus recognition sites which overlap with two Egr-1 consensus sites was shown to mediate phorbol ester induced PDGF-A chain expression in vascular endothelial cells. Stimulation of the cells with phorbol ester induced transient Egr-1 expression, and transient occurence of a Egr-1 containing nucleo-protein complex on the promoter fragment was observed. Binding studies demonstrated a competition between Sp1 and Egr-1 for recognition of the promoter region. Thus, in case of the PDGF-A chain promoter phorbol ester-induced Egr-1 transcription factor displaces Sp1 from the G+C-rich element and activates PDGF-A chain expression in endothelial cells (Khachigian et al., 1995) . Similar Sp1/Egr-1 displacement mechanisms in vascular endothelial cells were reported for the SIS proximal element in the PDGF-B promoter, and were postulated for the promoters of TGFb1, tissue factor, and urokinasetype plasminogen activator. Sp1, whose binding site in the PDGF-B chain promoter overlaps that of Egr-1, Figure 4a , respectively. Nucleo-protein complexes (I ± III) formed were analysed by electrophoresis on a 4% polyacrylamide gel. To identify the proteins bound to the DNA probes, reaction mixes were incubated with an anti-Sp1 antiserum, an anti-Sp3 antiserum, and an anti-Egr-1 antiserum, respectively occupies this element in unstimulated cells and is displaced by increasing amounts of Egr-1 upon injuryinduced Egr-1 expression (Khachigian et al., 1996) . Others (Liang et al., 1996a,b) reported that phorbol ester-induced expression of PDGF-B chain in megakaryocytes and constitutive expression of the growth factor in human osteosarcoma cells requires binding of transcription factors Sp1 and/or Sp3 to a common motif in the SIS proximal element. In contrast to the situation in endothelial cells, in megakaryocytes and in osteosarcoma cells constitutive binding of Sp1 and/or Sp3 was necessary for basal as well as for phorbol ester-induced transcription of the PDGF-B gene.
Increased binding of Sp1 to its respective recognition sites was reported as a further mechanism by which Sp1 mediates enhanced gene expression, for instance in PDGF-induction of the human low density lipoprotein receptor gene (Basheeruddin et al., 1995) and in phorbol ester-induction of the human platelet thromboxane receptor gene (D'Angelo et al., 1996) .
By site-directed mutagenesis and transfection analysis we have shown that the three Sp1 sites within the 785 to 750 region of the VEGF gene promoter are essential for PDGF-inducible expression in NIH3T3 cells. Mutation of the putative Egr-1 sites was without eect although PDGF-stimulation of the cells resulted in a transient induction of Egr-1 protein. No induction of Sp1 protein was observed upon PDGF-stimulation. This contrasts with the ®ndings of Ryuto et al. (1996) , who reported on elevated Sp1 expression in tumor necrosis factor a-and basic ®broblast growth factorinduced human glioma cells, and showed the importance of four potential Sp1 recognition sites within the region 7129 to +1 of the human VEGF promoter for induction by these factors. Here, we demonstrated by gel shift and supershift studies that Sp1 and Sp3, or immunological related proteins, bind in a constitutive manner to the Sp1 consensus sites within the 785 to 750 region of the VEGF promoter. No interaction of a member of the Egr transcription factor family with this fragment was observed. Although overlapping Sp1 and Egr-1 sites occur in the proximal promoter regions of human VEGF, PDGF-A, and PDGF-B genes the mechanisms of promoter activation appear to be dierent. Whereas a Sp1/Egr-1 displacement mechanism acts upon phorbol ester-and injury-induced stimulation of PDGF-A and PDGF-B genes in endothelial cells, PDGF-BB-induced expression of VEGF in NIH3T3 cells closely resembles PDGF-B gene expression in megakaryocytes and in osteosarcoma cells depending on constitutive binding of Sp1 and/or Sp3.
The molecular mechanism underlying transcriptional activation of the VEGF gene promoter upon PDGFstimulation via constitutively bound Sp1 and Sp3 transcription factors remains speculative. Sp1 is a potent activator for a wide variety of GC-motif containing promoters, whereas Sp3 has been described as an inhibitory member of the Sp transcription factor family acting by competition with Sp1 for their common binding sites (Hagen et al., 1994; Majello et al., 1995) . In contrast, for the PDGF-B gene promoter both Sp1 and Sp3 function as activators of transcription (Liang et al., 1996a,b) . In supershift experiments using either Sp1 or Sp3 antibodies, we did not observe any variation in the ratio of Sp1 to Sp3 bound to the 785 to 750 region of the VEGF promoter upon PDGF-stimulation, a result that argues against the involvement of a putative Sp1/Sp3 displacement mechanism.
In reconstitution experiments several independent positive cofactors were discovered which serve as adaptor molecules between Sp1 (or other transcriptional activator proteins) and the general transcription initiation machinery (Pugh and Tijan, 1990; recently reviewed in: Kaiser and Meisterernst, 1996) . Presumably, such coactivator proteins may be involved in transducing the PDGF signal into transcriptional activation by coupling constitutively bound Sp1 and/ or Sp3 to the pre-initiation complex. Regulation of promoter activation by constitutively bound transcription factors has been studied in detail with the c-fos proto-oncogene promoter (recently reviewed in : Cahill et al., 1996) . The c-fos proto-oncogene is rapidly and transiently induced by a variety of external stimuli including serum, growth factors (e.g. PDGF), cytokines, and phorbol esters. The most important DNA element which mediates signal-induced c-fos expression appears to be the serum response element, which is constitutively bound by the serum response factor and a ternary complex factor (Herrera et al., 1989) . The ternary complex factors are phosphorylated by mitogen-activated protein kinases, which enhances their transactivation potential and thus leads to c-fos upregulation via the serum response element. Recently it was shown that ternary complex factor Sap-1a interacts with the coactivator CBP, which functionally coactivates Sap-1a-dependent transcription upon Sap1a phosphorylation by mitogen-activated kinase . Although Sp1 becomes phosphorylated by a nuclear DNA-dependent protein kinase within its transcriptional activation domains upon SV40 infection of cells (Jackson et al., 1990) , the involvement of Sp1 phosphorylation in transactivation of target genes upon PDGF-stimulation remains to be elucidated.
After submission of this paper, Gille et al. (1997) reported on the involvement of AP-2 transcription factor in TGFa-induced transcriptional activation of the VEGF gene promoter in A431 human epidermoid carcinoma cells. By 5'-deletion analysis and gel shift techniques they identi®ed an AP-2 consensus site to be necessary for TGFa responsiveness of the VEGF gene promoter. This site overlaps with the second Sp1 site and is identical to the 5' putative Egr-1 site as depicted in Figure 4a . Transcription factors AP-2 and EGR-1 were shown to interact with this AP-2 site, and transfection of the cells with an AP-2, but not with an Egr-1, expression vector enhanced promoter activity suggesting that AP-2 is involved in mediating the TGFa signal. Introduction of two nucleotide substitutions (G 779 to T, G 778 to A) abolished TGFa responsiveness of the VEGF gene promoter. In our analysis of PDGF-induced VEGF gene promoter activation, we have introduced exactly the same nucleotide substitutions, for which Gille et al. (1997) have shown to abolish TGFa responsiveness, into our reporter plasmid pLuc135/Egr-1 mut, which we used to elucidate the role of the putative Egr-1 sites. In contrast to the situation with TGFa, introduction of these nucleotide substitutions into the AP-2/putative Egr-1 site did not abolish PDGF responsiveness of the VEGF gene promoter (Figure 4b ). From these data we conclude that PDGF and TGFa signaling involves dierent mediators to activate VEGF gene expression.
Our results strongly suggest transcription factors Sp1 and/or Sp3 as predominant downstream mediators of the PDGF signal in PDGF-induced VEGF expression. The signaling pathway between the PDGF receptors leading to activation of Sp1 and/or Sp3 transcription factors is currently under investigation.
Materials and methods
VEGF promoter-luciferase constructs
The 5.1 kb VEGF promoter fragment, containing the ®rst two exons of VEGF and the 3.4 kb sequence upstream to the translation initiation site (Tischer et al., 1991) , was kindly provided by JA Abraham. The 5.1 kb EcoRI fragment was digested with AccI and NheI and the resulting 2068 bp VEGF promoter fragment (72018 to +50, relative to the transcriptional start site) was cloned into AccI and XhoI of the promoterless luciferase reporter vector pAH 1409 (Hecht, 1990) to generate pLuc 2068.
5'-deletions were made using convenient restriction sites within the VEGF promoter and the pAH 1409 multiple cloning site. To generate pLuc 1340, pLuc 2068 was digested with AccI and BamHI, thus deleting 728 bp from the 5'-terminus following ®ll-in reaction with Klenow fragment and re-ligation. pLuc 840 was generated by digestion of pLuc 1340 with PstI following re-ligation. pLuc 465 was generated by digestion of pLuc 1340 with PstI and BglII, ®lling-in sticky ends by T4 DNA polymerase and re-ligation of the plasmid. pLuc 318 was constructed by cutting pLuc 1340 with PstI and SacII, ®ll-in reaction with Klenow fragment and re-ligation. Polymerase chain reaction was used to generate pLuc 135, pLuc 102, pLuc 135/Sp 1-mut, and pLuc 135/Egr-1 mut. A 3'-primer corresponding to position +20 to +50 relative to the transcriptional start site, which contained an additional XhoI site (Prom.B, 5'-AGCTC-GAGCCCAGCGCCACGACCTCCGAGCTACCCG-3'), a 5'-primer corresponding to the positions 785 to 772, which contained an additional PstI site (®n 1, 5'-ACCTGC-AGGGGCGGGCCGGGG-3'), and pLuc 2068 DNA as a template, were used to amplify a 135 bp fragment, which was digested with PstI and XhoI and ligated into pAH 1409 to generate pLuc 135. pLuc 102 was generated by using the 3'-primer Prom.B and a 5'-primer corresponding to positions 752 to 735 (Prom.C, 5'-CGCTGCAGAGCCATGCG-CCCCCCCC-3') for ampli®cation. To generate a reporter plasmid that contains mutated Sp1 sites, a 5'-primer corresponding to positions 785 to 752, in which the 3 Sp1 sites were mutated from GGGCGG to GTTCGG (135-SP-1-mut, 5'-ACCTGCAGGTTCGGGCCGGGTTCGGG-GTCCCGGCGGTTCGG-3') was ampli®ed with the 3'-primer Prom.B. The resulting 135 bp fragment was digested with PstI and XhoI and ligated into pAH 1409 generating pLuc 135/Sp 1-mut. pLuc 135/Egr-1 mut, a reporter plasmid in which two putative Egr-1 sites, located at positions 767 to 759 and 750 to 742 relative to the transcriptional start site, are mutated from CCGGGGGCG to CCTAGGGCG and from GCGGGGCGG to GCTAGGCGG, respectively, was constructed by using a 5'-primer (Egr-1-mut, 5'-GCCTGCAGGGGCGGGCCTAGGGCGGGGTCCCGGC-TAGGC-3') for ampli®cation with the 3'-primer Prom.B. The resulting 135 bp fragment was digested with PstI and XhoI and ligated into pAH 1409 generating pLuc 135/Egr-1 mut. The heterologous pTATA (785/750) promoter construct was created by ligating a double-stranded oligonucleotide containing the VEGF promoter sequence from bp 785 to bp 750 via additional HindIII and BamHI sites into plasmid pTATA (Hecht, 1990) , which contains the thymidine kinase gene promoter from plasmid pBL CAT2 (Luckow and Schulz, 1987) upstream of the luciferase reporter gene. Each construct was veri®ed by DNA sequence analysis. The various luciferase constructs are schematically depicted in Figure 1 .
Cell culture and transfection
NIH3T3 cells were grown in Dulbecco's modi®ed essential medium (DMEM), supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 U/ ml streptomycin, in 378C, 10% CO 2 . Transient transfection assays were performed with 2 mg of reporter plasmid and 1 mg of the b-galactosidase expression plasmid pCMV b-gal (Stratagene) by the calcium phosphate-DNA coprecipitation method (Chen and Okayama, 1988) using the Stratagene mammalian transfection kit. For PDGF-BB treatment, cells were serum-starved for 24 h following stimulation with PDGF-BB (50 ng/ml) for 3 h. Cell extracts were prepared using reporter lysis buer (Promega). Luciferase activity in cell extracts was assayed according to standard protocols (Ausubel et al., 1987) using a Dynatech luminometer (Dynatech Laboratories). Luciferase activities were normalized for transfection eciency by measurement of b-galactosidase activity, which was expressed from a cotransfected b-galactosidase gene under control of the CMV promoter.
Western blot analyses
Cells were lysed on ice by the addition of lysis buer (20 mM Tris-HCl, pH 7.5, 1 mM EGTA, 2 mM EDTA, 10% glycerine, 140 mM NaCl, 1 mM sodium orthovanadate, 40 mg/ml phenylmethanesulphonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml soybean trypsin inhibitor, 1% Triton X-100). The protein concentration was determined using the BCA protein assay kit (Pierce). Proteins were separated by 8% SDS-polyacrylamide gel electrophoresis, transferred to Hybond ECL nitrocellulose membranes (Amersham), and probed with polyclonal antibodies against Sp1 or Egr-1 (Santa Cruz). Detection was performed after incubation of the membranes with anti-rabbit horseradish peroxidase conjugate (Dianova) for 1 h at room temperature using an ECL Western blotting detection system (Amersham) as described by the manufacturer.
Extraction of nuclear proteins and electrophoretic mobility shift assay NIH3T3 nuclear extracts were prepared as described in Baeuerle and Baltimore (1988) . In brief, cells were lysed in lysis buer containing 20 mM HEPES, 350 mM NaCl, 20% glycerol, 1% Nonidet P-40, 1 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM DTT, 1 mM Pefablock, 1 mg/ml aprotinin and 1 mg/ml leupeptin. Cells were scraped o and transferred in Eppendorf-tubes. Nuclei were pelleted by centrifugation and the supernatant containing nuclear proteins was collected and stored at 7808C. Doublestranded oligonucleotide probes were end-labeled by incubation with T4 polynucleotide kinase (Pharmacia) and [
32 P]ATP. After separation from unincorporated [ 32 P]ATP using MicroSpin S-300 HR columns (Pharmacia), the radioactive labeled oligonucleotides (10000 c.p.m.) were incubated with 5 mg of nuclear proteins for 20 min at room temperature. In supershift assays 1 ml of antibodies (Santa Cruz) directed against the various transcription factors were incubated within the binding mixture for 30 min at room temperature prior to the addition of the oligonucleotide probe. The complexes were separated on 4% polyacrylamide gels under non-denaturating conditions.
